Spiramycin(Synonyms: 螺旋霉素; Rovamycin)

发表于由

天然产物 糖类和糖苷 Saccharides and Glycosides

Spiramycin;(Synonyms: 螺旋霉素; Rovamycin) 纯度: 98.56%

Spiramycin (Rovamycin) 是由链霉菌 (Streptomyces ambofaciens) 产生的大环内酯抗生素，具有抗细菌和抗弓形虫的作用，并具有抗寄生虫作用。Spiramycin (Rovamycin) 由 16 个内酯环组成，其上附着三种糖 (mycaminose，forosamine 和 mycarose)。

Spiramycin(Synonyms: 螺旋霉素; Rovamycin)

Spiramycin Chemical Structure

CAS No. : 8025-81-8

规格 价格 是否有货 数量
10;mM;*;1 mL in DMSO ￥790 In-stock
100 mg ￥600 In-stock
200 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

Spiramycin 相关产品

bull;相关化合物库:

  • Covalent Screening Library Plus
  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Natural Product Library
  • FDA-Approved Drug Library
  • Drug Repurposing Compound Library
  • Covalent Screening Library
  • Macrocyclic Compound Library
  • Antibacterial Compound Library
  • Anti-COVID-19 Compound Library
  • NMPA-Approved Drug Library
  • Medicine Food Homology Compound Library
  • FDA Approved amp; Pharmacopeial Drug Library
  • Antibiotics Library
  • Antiparasitic Compound library
  • Microbial Metabolite Library
  • Rare Diseases Drug Library

生物活性

Spiramycin (Rovamycin) is a macrolide antibiotic produced by Streptomyces ambofaciens with against bacteria and Toxoplasma gondii activities, and also has antiparasitic effect. Spiramycin is composed of a 16-member lactone ring, on which three sugars (mycaminose, forosamine, and mycarose) are attached[1][2].

IC50 Target

Bacterial[1]
体外研究
(In Vitro)

Spiramycin (24 hours; 1-1000 μM; T. gondii infected HeLa cells and HeLa cells) treatment reduces the cytotoxicity, and shows anti-Toxoplasma gondii activity, with IC50 values of 189 μM for HeLa cells; and 262 μM for T. gondii-infected HeLa cells[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[3]

Cell Line: T. gondii infected HeLa cells and HeLa cells
Concentration: 1-1000 μM
Incubation Time: 24 hours
Result: Reduced the cytotoxicity.

体内研究
(In Vivo)

Spiramycin (100 mg/kg; intraperitoneal injection; every day; for 4 days; female KM mice) treatment reduces the number of tachyzoites, and reduces hepatotoxicity and significantly enhances antioxidative effects. Spiramycin treatment also decreases in the degree of granulomatous inflammation in the liver[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 36 female KM mice with T.gondii[3]
Dosage: 100 mg/kg
Administration: Intraperitoneal injection; every day; for 4 days
Result: The number of tachyzoites was significantly reduced. Reduced hepatotoxicity and significantly enhanced antioxidative effects. Granuloma and cyst formation were inhibitied.

Clinical Trial

分子量

843.05

Formula

C43H74N2O14
CAS 号

8025-81-8
中文名称

螺旋霉素
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20deg;C 3 years
4deg;C 2 years
In solvent -80deg;C 6 months
-20deg;C 1 month
溶解性数据
In Vitro:;

DMSO : ≥ 100 mg/mL (118.62 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.1862 mL 5.9308 mL 11.8617 mL
5 mM 0.2372 mL 1.1862 mL 2.3723 mL
10 mM 0.1186 mL 0.5931 mL 1.1862 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂：;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (2.97 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.97 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂：;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.97 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.97 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂：;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.97 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.97 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献

  • [1]. Nguyen HC, et al. Post-PKS tailoring steps of the spiramycin macrolactone ring in Streptomyces ambofaciens. Antimicrob Agents Chemother. 2013 Aug;57(8):3836-42.

    [2]. Etewa SE, et al. Assessment of spiramycin-loaded chitosan nanoparticles treatment on acute and chronic toxoplasmosis in mice. J Parasit Dis. 2018 Mar;42(1):102-113.

    [3]. Guo HY, et al. Synthesis and Biological Evaluation of (+)-Usnic Acid Derivatives as Potential Anti-Toxoplasma gondii Agents. J Agric Food Chem. 2019 Aug 28;67(34):9630-9642.